$INAB

IN8bio (NASDAQ: INAB) reported a Q1 2026 net loss of $5.1 million, an improvement from the $5.6 million loss in Q1 2025. The company's cash balance of $21.9 million as of March 31, 2026, is expected to fund operations only through April 2027, leading to "substantial doubt" about its ability to continue as a going concern. IN8bio highlighted plans to seek additional financing and collaborations while prioritizing its pipeline, which includes clinical-stage programs for leukemias and glioblastoma, and preclinical T cell engager candidates for autoimmune diseases.